Table 1

Summary of all the basic characteristics of the included studies

Clinical trial informationFirst authorYearPhaseHistologyTreatmentNumber of patientsAge in years (median)Male (%)Current or former smoking (%)
NCT02041533DP Carbone2017IIINSCLCNivolumab271636888
Platinum-based chemotherapy270655587
NCT02142738Martin Reck2016IIINSCLCPembrolizumab15464.559.796.8
Platinum-based chemotherapy1516662.987.4
NCT02220894Tony S K Mok2019IIINSCLCPembrolizumab637637178
Platinum-based chemotherapy637637178
NCT02578680L Gandhi2018IIINon-squamous NSCLCPembrolizumab plus pemetrexed and a platinum-based drug410656288.3
Placebo plus pemetrexed and a platinum-based drug20663.552.987.9
NCT02039674Hossein Borghaei2018IINon-squamous NSCLCPembrolizumab plus carboplatin and pemetrexed6062.53775
Carboplatin and pemetrexed6363.24186
NCT02775435Luis G Paz-Ares2018IIISquamous NSCLCPembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel2786579.192.1
Placebo plus carboplatin and paclitaxel/nab-paclitaxel2816583.693.2
NCT02477826Hossein Borghaei2018IIINSCLCNivolumab plus platinum-doublet chemotherapy177647384
Platinum-doublet chemotherapy186646785
NCT02367794Robert M. Jotte2018IIISquamous NSCLCAtezolizumab plus carboplatin and nab-paclitaxel343658191
Carboplatin and nab-paclitaxel340658293
NCT02657434Vassiliki A. Papadimitrakopoulou2018IIINon-squamous NSCLCAtezolizumab plus carboplatin/cisplatin and pemetrexed2926465.887.3
Carboplatin/cisplatin and pemetrexed2866367.189.5
NCT02367781Howard West2019IIINon-squamous NSCLCAtezolizumab plus carboplatin plus nab-paclitaxel483645787
Carboplatin plus nab-paclitaxel240655892
  • NSCLC, non-small cell lung cancer.